Latest Anti-diabetic drug Stories
Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago.
NEW YORK, Nov.
Continuous Glucose Monitoring Systems Market to Grow 48% in 2009 VANCOUVER, Oct. 6 /PRNewswire/ - According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S.
Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment.
Canadian scientists say they have discovered rosiglitazone (Avandia) a type 2 diabetes drug, might be linked with increased risk of heart failure and death. The scientists from the University of Toronto and the Sunnybrook Health Sciences Center in Toronto, said the linkage was found among older patients, compared to a similar drug, pioglitazone (Actos). The scientists used prescription records to identify nearly 40,000 patients aged 66 years and older who started treatment with either...
Release Highlights - Melogliptin continues to demonstrate potential to be the best-in-class in achieving glycemic control with low incidence of hypoglycemia and neutral effect on body weight - Global Phase III trials likely to start by end 2009 - IND approved by USFDA - Glenmark takes a step closer towards becoming the first Indian company to have a truly global innovative drug for the world In the recently completed 12 week Phase IIb clinical...
Promise is held out for the development of novel oral drugs to control blood glucose levels in diabetes patients as the result of research by a Hebrew University of Jerusalem scientist.
LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain. The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus (T2DM) patients previously...
- Results Reported at the American Diabetes Association Meeting Validate Mechanistic and Therapeutic Potential of sEH Inhibitor in Treating Type 2 Diabetes - SOUTH SAN FRANCISCO, Calif., June 9 /PRNewswire/ -- Arete Therapeutics Inc.
- Year-Long Phase 2 Diabetes Study Results Presented at ADA Annual Meeting - NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- VIVUS, Inc.
- A poem in which the author retracts something said in an earlier poem.